Literature DB >> 9202340

Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?

A J Cooper1, K F Sheu, J R Burke, O Onodera, W J Strittmatter, A D Roses, J P Blass.   

Abstract

Huntington's disease and six other neurodegenerative diseases are associated with abnormal gene products containing expanded polyglutamine (poly-Q; Qn) domains (n > or = 40). In the present work, we show that glutathione S-transferase (GST) fusion proteins containing a small, physiological-length poly-Q domain (GSTQ10) or a large, pathological-length poly-Q domain (GSTQ62) are excellent substrates of guinea pig liver (tissue) transglutaminase and that both GSTQ10 and GSTQ62 are activators of tissue transglutaminase-catalyzed hydroxaminolysis of N-alpha-carbobenzoxyglutaminylglycine. The present findings have implications for understanding the pathophysiological mechanisms of expanded CAG/poly-Q domain diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202340     DOI: 10.1046/j.1471-4159.1997.69010431.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 2.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

3.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

4.  Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases.

Authors:  H Monoi; S Futaki; S Kugimiya; H Minakata; K Yoshihara
Journal:  Biophys J       Date:  2000-06       Impact factor: 4.033

Review 5.  Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Janghoo Lim
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

6.  Identification of tissue transglutaminase-reactive lysine residues in glyceraldehyde-3-phosphate dehydrogenase.

Authors:  Stefania Orru; Margherita Ruoppolo; Simona Francese; Luigi Vitagliano; Gennaro Marino; Carla Esposito
Journal:  Protein Sci       Date:  2002-01       Impact factor: 6.725

7.  Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length.

Authors:  K L Moulder; O Onodera; J R Burke; W J Strittmatter; E M Johnson
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

8.  Inhibition of α-ketoglutarate-and pyruvate dehydrogenase complexes in E. coli by a glutathione S-transferase containing a pathological length poly-Q domain: A possible role of energy deficit in neurological diseases associated with poly-Q expansions?

Authors:  A J Cooper; K F Sheu; J R Burke; O Onodera; W J Strittmatter; A D Roses; J P Blass
Journal:  Age (Omaha)       Date:  1998-01

Review 9.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

Review 10.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.